PBE News and Press, Invesco Dynamic Biotech & Genome From 05/06/22

A phase 2a study using Lomecel-B for Alzheimer's Disease is currently enrolling patients; a prior phase 1 study established excellent safety profile with some efficacy. The global Alzheimer's Disease market could reach $25 billion by 2027. Lomecel-B has several shots on goal; besi...

FBT doesn’t pay any dividend and had a negative price growth over the short term. Barring the inverse funds, all other biotechnology ETFs had a high negative growth over the past 12 months. FBT’s price multiples are around category average, and current price is quite...

KPTI has been devastated by the SIENDO trial failure. The next trial's data will be read out 2 years later. Until then, I see little upside for the stock. For further details see: Karyopharm: Another 2 Year Wait For Data

MorphoSys stock has taken a huge hit since its Constellation buyout. The company has staked an entire existing revenue stream for a development stage asset. The market hasn't taken this kindly. For further details see: MorphoSys May Not Recover From Adventurous Constella...

During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market. Huge price loss in the past 12 months, but positive price gain in the past three years, is an apparently visible trend in Genomics-...

Biotechnology exchange traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) hovers near its one-year trading low, but the investment community has shown recent interest in the fund as the ETF has experienced a large influx of capital in 2022. While XBI trades down 27% on the yea...

Historically, RYH has generated a return in the range of 14 to 24 percent. As an equal weight healthcare ETF, returns of RYH are less volatile. RYH’s price multiples and SMAs indicate a possible overvaluation. For further details see: RYH: Equal Weight Healthcare ...

Since the beginning of COVID-19, companies and countries have struggled to ensure steady supply of key inputs to the normal functioning of our economies. Synthetic biology is a revolutionary technology that could make a profound impact on the way a vast array of products are manufactu...